Los fabricantes de medicamentos genéricos inflaron los precios hasta un 1000% en EEUU, según una demanda histórica
Kelley Dougherty - Head of Corporate Affairs — Teva Pharmaceuticals, North America - Teva Pharmaceuticals | LinkedIn
Kelley Dougherty - Underwriting assistant for-Jumbo Non Delegated - Guaranteed Rate | LinkedIn
Teva recalls US-made drugs following contamination fears - The Boston Globe
Teva Plans to Cut Back Generic Drug Production Even As Shortages Intensify - BNN Bloomberg
Kelley Dougherty - United States | Professional Profile | LinkedIn
Teva Announces Leadership Change in its Global Operations Group | BioSpace
Kelley Dougherty - United States | Professional Profile | LinkedIn
Escasea el Adderall, un medicamento para el TDAH - Consumer Health News | HealthDay
Teva reaches $925K settlement with Mississippi in price-fixing case—and it hopes other states will follow suit | Fierce Pharma
Teva Announces Appointment of New Global R&D and Chief Medical Officer | Business Wire
Kelley Dougherty on LinkedIn: #tevagives #holidaygiving #tevaproud
Kelley Dougherty - Head of Corporate Affairs — Teva Pharmaceuticals, North America - Teva Pharmaceuticals | LinkedIn
Kelley Dougherty - Head of Corporate Affairs — Teva Pharmaceuticals, North America - Teva Pharmaceuticals | LinkedIn
Teva Wins Patent Case Related to Orexo Opioid-Treatment Drug - Bloomberg
Kelley Dougherty - United States | Professional Profile | LinkedIn
Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland, join a growing list of provinces providing public drug plan reimbursement for Teva Canada's AJOVY® (fremanezumab), for the preventive treatment of migraine in
TEVA REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS • Revenues of $4.4 billion • GAAP diluted EPS of $0.06 • Non-GAAP dilute
Teva Canada Charts a New Prescription for Care
Kelley Dougherty - United States | Professional Profile | LinkedIn
Kelley Dougherty - United States | Professional Profile | LinkedIn
Teva, Units Held Liable for Fueling N.Y. Opioid Crisis - Bloomberg
Teva Reports First Quarter 2023 Financial Results and Reaffirms 2023 Non-GAAP Outlook
Teva's Adderall Shortage Expected to Continue Into March, FDA Says - BNN Bloomberg
Teva Pharmaceuticals at heart of major price fixing suit in US - www.israelhayom.com
